Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The term cancer is used to describe many conditions, and cancer's complexity and diversity is reflected in cancer treatments as well. It is not surprising, therefore, that a quarter of all drug approvals in the United States are for oncology.1 Before these drugs are approved, they go through a multistep process of approval—preclinical studies, clinical trials, regulatory review, etc—to generate data demonstrating safety and efficacy.
Oncology clinicians are using an increasing number of tumor next-generation sequencing (NGS) tests to help determine treatment options for patients with cancer, including for use of standard-of-care targeted therapies, enrollment on clinical trials, and use of off-label treatments. With increased testing and the growing size of panels, more variants are being uncovered.
Approximately 40% of cancer-related clinical trials terminate prematurely,1 which results in an immense loss of time, money, and human effort. Failure to optimize clinical trial design, inefficient enrollment processes, and poor accrual rates are the main reasons for premature trial closure.1 As successful trial accrual is paramount to drug discovery, efforts to address this challenge are urgently needed.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
